GSK to Invest $30B in R&D and Manufacturing in the U.S. 

GSK plc plans to invest $30 billion across the U.S. in research and development and supply chain infrastructure over the next five years. This includes a new $1.2 billion investment in advanced manufacturing facilities and AI and advanced digital technologies, to deliver next-generation biopharma factories and labs in the U.S.  

The $1.2 billion investment includes:

Construction of an additional new biologics flex factory at Upper Merion, PA to deliver potential best-in-class new medicines for respiratory disease (COPD, asthma) and cancer (hematological, gynecological, lung and other solid tumors). Construction is planned to begin in 2026

New AI and advanced digital technology capabilities across GSK’s existing 5 manufacturing sites in Pennsylvania, North Carolina, Maryland, and Montana.

New drug substance manufacturing capabilities

New and enhanced device and auto-injector capabilities and assembly

The $30 billion investment in the U.S. includes capital investments across GSK’s U.S. supply chain, as well as increased investment in R&D drug discovery and development and clinical trial activity, with the U.S. expected to rank first globally for the number of studies, sites and clinical trials participants conducted by GSK over the next five years.

GSK has committed new investments of approximately $2 billion in U.S. manufacturing over the last 12 months. In October 2024, construction began of a new $800 million facility at GSK’s Marietta, PA site, doubling the size and capacity of the site. These new manufacturing investments will create hundreds of highly skilled jobs, building on GSK’s approximately 15,000 strong U.S. workforce.

GSK CEO Emma Walmsley said, “Alongside the many longstanding and vital shared interests that connect the U.K. and the U.S., is advancing life sciences to get ahead of disease. This week’s State Visit brings together two countries that have led the world in science and healthcare innovation. Today, we are committing to invest at least $30 billion in the U.S. over the next 5 years, further bolstering the already strong R&D and supply chain we have in the country.”